Triptorelin

FDA approved

Triptorelin (Trelstar, Triptodur) is a GnRH agonist approved by the FDA in 2000 for advanced prostate cancer, and later for central precocious puberty in children.

At a glance

Where it acts: Sexual & reproductive
Regulatory status: FDA approvedApproved by the U.S. FDA for at least one medical use.

Mechanism of Action

Triptorelin is a 10-amino acid GnRH analog. After an initial surge in LH and FSH, continuous dosing downregulates pituitary receptors and suppresses testosterone and estrogen.

Typical Dosage (Research)

Prescription-only medicine. Dosing is set by a physician according to the FDA-approved label and the condition being treated.

Side Effects & Risks

Hot flashes, skeletal pain, injection site pain, headache and impotence.

Tumor flare at the start of therapy, bone density loss, metabolic and cardiovascular effects of low testosterone, and seizures in some patients.

Who Uses Triptorelin

Men with advanced prostate cancer; children 2 and older with central precocious puberty.